Squamous Cell Carcinoma of Head and Neck

Oncology·MeSH: Squamous Cell Carcinoma of Head and Neck

Prevalence

14.0 / 100K

Incidence

6.0 / 100K/yr

23 drugs in development·10 companies·24 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
5-flurouracil	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
platinum based chemotherapy	GH Research PLC (GHRS)
rp1 in combination with nivolumab	Replimune Group, Inc. (REPL)

Phase 2(11)

Drug	Company
Amivantamab	Structure Therapeutics Inc. (GPCR)
Amivantamab and Recombinant Human Hyaluronidase	Structure Therapeutics Inc. (GPCR)
Amivantamab IV	Structure Therapeutics Inc. (GPCR)
Amivantamab SC	Structure Therapeutics Inc. (GPCR)
Sacituzumab Govitecan	FATE THERAPEUTICS INC (FATE)
sar444245	Sanofi (SNY)
Setanaxib	Calliditas Therapeutics AB (CALT)
vobramitamab duocarmazine	MACROGENICS INC (MGNX)
Vobramitamab Duocarmazine (vobra duo)	MACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.0 mg	MACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.7 mg	MACROGENICS INC (MGNX)

Phase 1(5)

Drug	Company
aldesleukin	GH Research PLC (GHRS)
jnj-90301900	JOHNSON & JOHNSON (JNJ)
jnj-90301900	Innovation Pharmaceuticals Inc. (IPIX)
RP3	Replimune Group, Inc. (REPL)
tbio-4101	GH Research PLC (GHRS)

Phase 1/Phase 2(1)

Drug	Company
cetuximab	Sanofi (SNY)

Phase 4(1)

Drug	Company
5-Flurouracil	Merus N.V. (MRUS)

BioSniper tracks 23 drugs in development for Squamous Cell Carcinoma of Head and Neck across 10 companies.

There are 24 clinical trials targeting Squamous Cell Carcinoma of Head and Neck tracked by BioSniper.

The estimated prevalence of Squamous Cell Carcinoma of Head and Neck is approximately 14.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.